SCHEMBL901671

SCHEMBL901671

CCOC(=O)CCc1cccc(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.55
CYP4A11 Q02928 2/20 0.55
FFAR1 O14842 1/20 0.52
FFAR4 Q5NUL3 1/20 0.52
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ALOX5 P09917 1/20 0.48
KDM4E B2RXH2 1/20 0.48
EPHX2 P34913 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PLAAT3 P53816 1/20 0.48
PLAAT5 Q96KN8 1/20 0.48
PLAAT2 Q9NWW9 1/20 0.48
PLAAT4 Q9UL19 1/20 0.48
CYP4Z1 Q86W10 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19899012 0.91 ALOX5 (0.54) CYP4F2CYP4A11FFAR1FFAR4MAPT
SCHEMBL9164347 0.89 PPARA (0.49) CYP4F2CYP4A11FFAR1FFAR4
SCHEMBL4425984 0.89 CYP4F2 (0.64) CYP4F2CYP4A11TDP1ALOX5CYP4Z1
SCHEMBL4326400 0.88 FFAR1 (0.48) FFAR1FFAR4MAPTMAPK1ALOX5
SCHEMBL23792071 0.86 LTA4H (0.51) EPHX2KMT2ASMN1; SMN2PLAAT3PLAAT5
SCHEMBL7059318 0.85 PLAAT3 (0.52) FFAR1FFAR4MAPTMAPK1ALOX5
SCHEMBL879289 0.84 CYP4F2 (0.58) CYP4F2CYP4A11FFAR4TDP1ALOX5
SCHEMBL406058 0.84 MAOB (0.58) MAPTMAPK1ALOX5KDM4EEPHX2
SCHEMBL13104077 0.84 CYP4F2 (0.58) CYP4F2CYP4A11MAPTMAPK1TDP1
SCHEMBL9545043 0.84 KMT2A (0.54) FFAR1FFAR4KMT2ASMN1; SMN2PLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164448-A Amino acid anilines as small molecule modulators of IL-17 利奥制药有限公司 2021-07-23 CN disclosed
CN-108863797-A The preparation method of a kind of 3- (substitution/unsubstituted phenyl) -3- hydroxyl propionyl hydroxamic acid 吉首大学 2018-11-23 CN disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
CN-103328479-A 7-hydroxy-pyrazolo [1,5-a ] pyrimidine compounds and their use as CCR2 receptor antagonists PROXIMAGEN LTD 2013-09-25 CN disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
EP-2139895-A1 AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
WO-2008116742-A1 AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-02 WO disclosed
US-20080234277-A1 NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 US disclosed
CN-1015622-B Hydrogenated cinnamic acid derivative and its method for making HOFFMANN LA ROCHE (CH) 1992-02-26 CN disclosed
CN-1036952-A Hydrogenated cinnamic acid derivative and its method for making HOFFMANN LA ROCHE (CH) 1989-11-08 CN disclosed
US-4243683-A INSECTICIDES, MITICIDES MAY & BAKER LIMITED (GB) 1981-01-06 US disclosed
US-4218452-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-08-19 US disclosed
US-4159329-A BLOCKING AGENTS, ANTAGONISTS, ANTIHISTAMINES SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) 1979-06-26 US disclosed
US-4145546-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234277-A1 NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES CHRM1, CHRM2, CHRM4 CYP4F2 91/4885CYP4A11 112/4885FFAR1 239/4885
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CYP4F2 1184/4885CYP4A11 639/4885FFAR1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.